Programmes
Click on the highlighted text and dots or the menu to link directly to additional information about each of these topics.
| Candidate | Indication | Mechanism of Action | Programme Status | Partner | |||
|---|---|---|---|---|---|---|---|
| Discovery Phase | Preclinical Development | Clinical Phase I | Clinical Phase II | ||||
| IFN-β (SNG001) | COVID-19 | Virus Defence |  |
 |
|
 |
|
| IFN-β (SNG001) | COPD | Virus Defence | |
|
|
|
|
| LOXL2 inhibitors | IPF, NASH, Kidney Fibrosis & Cardiac Fibrosis | Anti-fibrotic | |
|
|
|
Pharmaxis |
Synairgen plc
Registered in England and Wales No. 5233429
Registered office
Mailpoint 810, Level F, South Block,
Southampton General Hospital,
Tremona Road,
Southampton, SO16 6YD, UK